A standard treatment regimen for classical Hodgkin lymphoma (cHL) appears to reduce fertility in men but not women, according to research presented at the EHA 2022 Hybrid Congress.
Male survivors of cHL had lower childbearing rates if they received treatment with BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) rather than ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine).
The same association was not seen among female survivors of cHL.
Researchers used data from registries in Sweden, Denmark, and Norway to conduct this study of fertility in cHL survivors.
The team identified 3187 cHL survivors — 75% who had received ABVD, 10.8% who had received 6 to 8 cycles of BEACOPP, and 14.2% who had received other regimens or had missing treatment information. The latter group was not included in this analysis.
In the ABVD group, the rate of first childbirth was 45.5 per 1000 person-years in men and 48.2 per 1000 person-years in women.
In the BEACOPP group, the rate of first childbirth per 1000 person-years was 23.8 in men and 39.9 in women.
Compared with men who received ABVD, men who received BEACOPP had an adjusted hazard ratio (HR) for first childbirth of 0.55 (95% CI, 0.38-0.80). Among women, the HR was 0.85 (95% CI, 0.57-1.28).
Disclosures are not available for this presentation.
Entrop JP, Weibull CE, Smedby KE, et al. Childbearing among classical Hodgkin lymphoma survivors treated with BEACOPP and ABVD in Sweden, Denmark, and Norway. Presented at EHA 2022; June 9-12, 2022. Abstract S202.
This article originally appeared on Cancer Therapy Advisor